Business
Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
Revenue of $189 million, year-over-year increase of 22% as reported and 18% organic with ...
About this update from Regenera Insights Inc.
[{"type":"text","content":"Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance\n\n\n\n\n\n Revenue of $189 million, year-over-year\n \n increase\n \n of\n \n 22%\n \n as reported and 18% organic with double-digit reported growth across all franchises\n \n\n\n\n Orders increased sequentially and greater than 20% year-over-year\n \n\n\n\n Increasing revenue guidance to a range of $729 to $737 million, which represents 14% -15.5% year-over-year non-COVID organic growth\n \n\n\n\n\n\n WALTHAM, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2025, covering the three- and nine- month periods ended September 30, 2025. Provided in this press release are financial performance highlights, updates to our guidance for the full year 2025 and access information for today’s webcast and conference call.\n \n\n Olivier Loeillot, President and Chief Executive Officer of Repligen said, “We had another outstanding quarter in Q3 with 18% organic growth. We are thrilled with the momentum we are seeing across our broad, differentiated portfolio and the continued execution by our team. This resulted in double-digit revenue growth across all franchises and geographies. Consumables and capital equipment revenues were strong again, with continued performance from biopharma and CDMOs.\n \n\n “Given our year-to-date performance of 16% organic non-COVID revenue growth and our very strong Q3 orders, we are raising our full-year revenue guidance again.”\n \n\n\n Q3 2025 BUSINESS HIGHLIGHTS\n \n\n\n\n\n Broad-based Growth\n \n . All franchises posted double-digit year-over-year revenue and order growth. Consumables and capital equipment revenues grew greater than 20%. Both CDMO and biopharma revenues increased over 20%. In addition, all geographies grew double-digits, led by Asia Pacific.\n \n\n\n SoloVPE® PLUS.\n \n As an example of our innovation engine, we launched SoloVPE PLUS earlier this year, providing customers with increased data collection speed and enhanced sensitivity. Given these advantages, we had a record quarter for Process Analytics equipment placements this quarter.\n \n\n\n Novasign Partnership.\n \n We announced a strategic partners...